CEO KEVIN LOBO

Device maker Stryker strikes $4.9 billion deal for Inari Medical

The deal for Inari bolsters Stryker's efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases. Under the terms of the deal, which was first reported by Reuters earlier on Monday, Stryker will pay $80 per share for Inari.